<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Data of literature on the role of <z:mp ids='MP_0001845'>inflammation</z:mp> factors in the pathogenesis of <z:hpo ids='HP_0001297'>stroke</z:hpo> are presented </plain></SENT>
<SENT sid="1" pm="."><plain>The study of myeloperoxidase level in the early <z:hpo ids='HP_0011009'>acute</z:hpo> phase of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> and dynamics of this parameter after the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> treatment with the α-<z:chebi fb="0" ids="30314">lipoic acid</z:chebi> preparation berlition was carried out </plain></SENT>
<SENT sid="2" pm="."><plain>It has been shown that the activation of systemic <z:mp ids='MP_0001845'>inflammation</z:mp> and related <z:mp ids='MP_0003674'>oxidative stress</z:mp> recorded in the early <z:hpo ids='HP_0011009'>acute</z:hpo> phase of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> needs pharmacological treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Neuroprotective action of α-<z:chebi fb="0" ids="30314">lipoic acid</z:chebi> related to the prevention of damaging effect of free radicals on cell membranes and reduction of <z:mp ids='MP_0003674'>oxidative stress</z:mp> intensity is a pathogenetic explanation for using its preparations in ischemic <z:e sem="disease" ids="C0221505" disease_type="Disease or Syndrome" abbrv="">brain lesions</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The decrease in plasma myeloperoxidase content after the treatment with berlition may consider as a criterion of its efficacy </plain></SENT>
</text></document>